Teprotumumab-trbw - Biologic Drug Details

Summary for teprotumumab-trbw

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for teprotumumab-trbw

Mechanism of Action	Insulin-like Growth Factor-1 Receptor Inhibitors
Established Pharmacologic Class	Insulin-like Growth Factor-1 Receptor Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for teprotumumab-trbw Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for teprotumumab-trbw Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for teprotumumab-trbw Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Teprotumumab-trbw

Last updated: February 24, 2026

What is Teprotumumab-trbw and its approved indications?

Teprotumumab-trbw is a monoclonal antibody developed by Horizon Therapeutics, marketed as Tepezza. It is approved by the U.S. Food and Drug Administration (FDA) since January 2020 for the treatment of thyroid eye disease (TED), also known as Graves' orbitopathy. It targets insulin-like growth factor-1 receptor (IGF-1R), reducing inflammation and tissue expansion in the orbit.

What is the current market landscape for biologic drugs in autoimmune and inflammatory diseases?

Biologic drugs represent a growing sector within the pharmaceutical industry, with global sales estimated at approximately $276 billion in 2022, accounting for roughly 27% of prescription drug revenue. Key segments include autoimmune disorders, cancers, and rare diseases. The landscape is characterized by high R&D costs, extensive patent protections, and limited generic competition.

How does Teprotumumab-trbw compare to other treatments for thyroid eye disease?

Prior to FDA approval, TED management relied on corticosteroids, orbital decompression surgery, and immunosuppressants such as rituximab. These alternatives have variable efficacy and safety profiles. In clinical trials, teprotumumab-trbw demonstrated a reduction in proptosis of 2.5 mm versus 0.2 mm with placebo, with a response rate of 83% versus 10%. Its targeted mechanism offers an improved safety profile and sustained benefits over existing therapies.

What are the sales and revenue forecasts for Teprotumumab-trbw?

Market research predicts that teprotumumab-trbw will reach peak sales of approximately $1.2 billion annually by 2028. Key drivers include increasing prevalence of Graves' disease (estimated at 1-2% in the U.S. population), improved awareness among healthcare providers, and expanded indications.

The initial sales were approximately $173 million in 2022. The compound's market penetration is expected to increase gradually due to delayed adoption post-approval, reimbursement negotiations, and physician familiarity.

What are the key factors influencing the financial trajectory?

Patent and exclusivity status

Teprotumumab has patent protection until at least 2035 in the U.S., offering market exclusivity. No biosimilars or generic competitors are currently authorized, enabling Horizon to maintain pricing power.

Pricing and reimbursement

The wholesale acquisition cost (WAC) for teprotumumab is roughly $14,900 per infusion, with a typical treatment course consisting of eight infusions. Payers negotiate discounts; net prices are estimated at 10-20% below WAC. Reimbursement policies in key markets influence access and sales growth.

Competitive landscape

No other targeted biologic is approved specifically for TED. Off-label use of immunosuppressants and corticosteroids remains a competitor. Development of alternative IGF-1R inhibitors or biologics could alter this landscape.

Market access and awareness

Physician education and patient advocacy are critical to increasing treatment uptake. As awareness expands, prescriptions are expected to rise, bolstering revenues.

How will market dynamics evolve over the next five years?

• Growing prevalence of Graves’ disease will expand the overall treated population.
• Physician familiarity with teprotumumab-trbw will increase, raising prescription rates.
• Pricing strategies and payer negotiations will influence net revenue margins.
• Potential for label expansions (e.g., treatment of other IGF-1R related disorders) could diversify revenue streams.
• Competitive entries or biosimilars could impact market share, especially after patent expiry.

What are the risks and uncertainties affecting financial forecasts?

• Delay or rejection of reimbursement codes or coverage.
• Emergence of competing therapies or biosimilars.
• Safety concerns or adverse events leading to market restrictions.
• Changes in regulatory policies affecting biologic pricing or exclusivity.

What is the total addressable market (TAM)?

An estimated 200,000 individuals in the U.S. have Graves' disease, with approximately 60-70% developing TED. The subset with moderate-to-severe disease suitable for biologic therapy is around 20,000-30,000 patients. Globally, the potential expands to hundreds of thousands, with markets in Europe, Japan, and emerging economies opening over time.

Key Takeaways

• Teprotumumab-trbw is a first-in-class biologic for TED, with high efficacy demonstrated in clinical trials.
• Its patent exclusivity, high price point, and targeted mechanism position it favorably for near-term revenue growth.
• Market penetration depends on physician adoption, reimbursement, and awareness.
• The global target market expands as treatment criteria and diagnosis improve.
• Competitive pressures and biosimilar developments pose risks beyond 2030.

FAQs

Q1: When is teprotumumab-trbw expected to face biosimilar competition?
A1: Patents extend until at least 2035; biosimilar development depends on patent challenges. Biosimilars typically enter markets 8-12 years post-approval, suggesting potential from 2028 onward.

Q2: What are the main safety considerations influencing market uptake?
A2: Common adverse events include muscle spasms, nausea, alopecia, diarrhea, and hyperglycemia. Safety profile independent of efficacy may affect clinician willingness to prescribe.

Q3: How will expanded indications impact sales?
A3: If approved for other IGF-1R-mediated conditions such as other autoimmune or fibrotic diseases, sales could increase significantly, adding hundreds of millions annually.

Q4: What geographic markets are most promising outside the U.S.?
A4: Europe, Japan, and Canada represent primary expansion opportunities, where regulatory approvals are forthcoming or achieved, and healthcare infrastructure supports biologic therapies.

Q5: What are the key regulatory challenges ahead?
A5: Post-marketing surveillance for safety signals and potential label updates, as well as navigating reimbursement policies, will influence long-term financial plans.

---

References

[1] FDA. (2020). FDA approves Tepezza to treat thyroid eye disease. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-tepezza-treat-thyroid-eye-disease

[2] Horizon Therapeutics. (2023). Tepezza (teprotumumab-trbw) prescribing information.

[3] IQVIA. (2022). The Global Use of Medicine in 2022.

[4] Evaluate Pharma. (2023). Biologics market forecast.